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Abstract
Background: Tuberculosis (TB) is the leading cause of death worldwide from a single infectious agent. An ability to detect
the Mycobacterium tuberculosis complex (MTC) in clinical material while simultaneously differentiating its members is
considered important. This allows for the gathering of epidemiological information pertaining to the prevalence,
transmission and geographical distribution of the MTC, including those MTC members associated with zoonotic TB infection
in humans. Also differentiating between members of the MTC provides the clinician with inherent MTC specific drug
susceptibility profiles to guide appropriate chemotherapy.
Methodology/Principal Findings: The aim of this study was to develop a multiplex real-time PCR assay using novel
molecular targets to identify and differentiate between the phylogenetically closely related M. bovis, M. bovis BCG and M.
caprae. The lpqT gene was explored for the collective identification of M. bovis, M. bovis BCG and M. caprae, the lepA gene
was targeted for the specific identification of M. caprae and a Region of Difference 1 (RD1) assay was incorporated in the
test to differentiate M. bovis BCG. The multiplex real-time PCR assay was evaluated on 133 bacterial strains and was
determined to be 100% specific for the members of the MTC targeted.
Conclusions/Significance: The multiplex real-time PCR assay developed in this study is the first assay described for the
identification and simultaneous differentiation of M. bovis, M. bovis BCG and M. caprae in one internally controlled reaction.
Future validation of this multiplex assay should demonstrate its potential in the rapid and accurate diagnosis of TB caused
by these three mycobacteria. Furthermore, the developed assay may be used in conjunction with a recently described
multiplex real-time PCR assay for identification of the MTC and simultaneous differentiation of M. tuberculosis, M. canettii
resulting in an ability to differentiate five of the eight members of the MTC.
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Introduction
Tuberculosis (TB) in humans is mostly caused by members of
the Mycobacterium tuberculosis complex (MTC), although infections
caused by nontuberculous mycobacteria (NTM) can mimic this
disease [1]. M. tuberculosis is considered to be the primary pathogen
of TB in humans [2]. Other members of the MTC associated with
human TB infection include M. canettii and M. africanum, with the
highest prevalence in various parts of Africa [3]. The remaining
members of the MTC including M. bovis, M. caprae, M. microti and
M. pinnipedii are considered predominantly animal pathogens,
apart from the, for vaccination purposes, attenuated M. bovis BCG
strain. However, all members of the MTC have been shown to
cause human TB infection [4]. For example, the major etiological
agents of zoonotic TB in humans are the phylogenetically related
M. bovis and M. caprae [5]. These members of the MTC occur
worldwide and there are indications which suggest the true
prevalence of zoonotic human TB infection may be underrepre-
sented, especially because of the extrapulmonary manifestation of
the disease generally caused by these bacteria [6,7,8]. In developed
countries it has been suggested that the burden of bovine TB in
humans ranges from 0.5 to 7.2% of TB cases, while in developing
countries, where very little data is available, this figure may be as
high as 15% [9,10].
The diagnosis of TB in humans in high prevalence setting
usually still relies on smear microscopy, although this is insensitive,
especially in patients co-infected with HIV [11,12].The gold
standard culture method is both time consuming and laborious
[13]. Therefore, in vitro nucleic acid amplification tests (NAATs)
offer a rapid and sensitive alternative to traditional methods for the
detection of TB infection, with an increasing number of com-
mercially available TB diagnostics kits becoming available [14,15,
16], in addition to NAAT methods described in the literature
[17,18]. However, most of these rapid and traditional diagnostics
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methods detect the presence of the MTC but do not identify the
specific etiological agent of infection.
Since the introduction of pasteurisation and bovine TB
eradication programmes in developed countries there has been a
significant reduction in the number of zoonotic TB cases in
humans [10], with the majority of such cases occurring as a result
of endogenous reactivation of a previous infection [9,19]. How-
ever, recent reports have identified TB in humans caused by M.
bovis in countries officially free from bovine TB [8] and suggest that
the true prevalence of zoonotic TB may be underestimated
clinically [7]. In addition, recent reports show that M. bovis
infection in younger patient groups in the Western world are still
common, most likely owing to consumption of raw milk (products)
in the country of origin [20]. Moreover, zoonotic TB remains a
significant threat to human health in developing countries where
its prevalence is currently unknown, as differentiation between the
members of the MTC is not routinely performed [9,21].
The accurate differentiation of the MTC is also clinically
important, due to varying natural resistances of members of the
MTC to anti-TB drugs. [22]. As such, the ability to differentiate
between members of the MTC could potentially allow for the
monitoring of zoonotic exposure leading to human TB infection,
in addition to providing accurate epidemiological information for
the clinician, guiding contact tracing and source case finding.
In this study, we report the design, development and testing of a
multiplex real-time PCR assay, using novel nucleic acid molecular
targets, to identify and simultaneously differentiate between M.
bovis, M. bovis BCG and M. caprae in one internally controlled
reaction. This assay can be used independently, or in combination
with, a recently described multiplex PCR assay for the iden-
tification of the MTC, M. tuberculosis and M. canettii [23].
Materials and Methods
Diagnostics target identification
The diagnostics target genes used in this study were identified
using a number of experimental and bioinformatics approaches.
Potential target regions were identified using the Mycobacterial
Genome Divergence Database (MGDD) (http://mirna.jnu.ac.in/
mgdd/), which allowed for identification of insertions, deletions
and single nucleotide polymorphisms between M. tuberculosis, M.
bovis and M. bovis BCG. Other potential target regions were
identified using the web based version of the Artemis comparison
tool, WebACT (http://www.webact.org/WebACT/home). Nu-
cleotide sequence information for M. africanum, M. microti and M.
canettii was retrieved from the Welcome Trust Sanger Institute
website (www.sanger.ac.uk/resources/downloads/bacteria/myco-
bacterium- currently being sequenced and annotated) to deter-
mine, in silico, if the candidate diagnostics target sequences for M.
bovis identification were specific. As there was no nucleotide
sequence information available for M. caprae or M. pinnipedii at the
time of this study, specificity of the developed assays against these
members of the MTC was determined empirically and further
validated by nucleotide sequencing.
Since the diagnostics target used in this study for the dif-
ferentiation of M. bovis from the remaining members of the
MTC was experimentally determined to also identify M. caprae and
M. bovis BCG, alternative nucleic acid diagnostics targets were
required to differentiate this sub-group of the MTC.
For each putative diagnostics target identified, alignments were
performed using clustalW multiple sequence alignment pro-
gramme (http://www.ebi.ac.uk/Tools/clustalw2/index.html), from
which real-time PCR primers and probes were designed (Table 1).
Bacterial strains, culture media and growth conditions
Seventy two MTC isolates (26 M. tuberculosis, 14 M. bovis, 7 M.
bovis BCG, 5 M. canettii, 5 M. caprae, 5 M. africanum, 5 M. microti and
5 M. pinnipedii), 44 non tuberculosis mycobacteria (NTM) and 17
other bacterial species were used in this study (supplementary
Table S1 and Table S2). Of the 72 MTC isolates, 36 strains
previously characterised by a variety of methods [24,25,26,27,28]
were provided by The National Institute for Public Health and the
Environment (RIVM), the Netherlands. Three M. caprae, 3 M. bovis
and 2 M. pinnipedii strains were supplied by the National Reference
Centre for Mycobacteria, Borstel, Germany and were previously
characterised using a variety of methods [29,30]. All other MTC
Table 1. Oligonucleotide primers and probes used in this study.
Name Purpose Sequence 59R39
MTC_Fw Forward sequencing primer,
forward M. caprae real- time PCR assay primer
AGACCGTGCGGATCTTG
MTC_Rv Reverse sequencing primer, reverse M. caprae real-time PCR assay primer CATGGAGATCACCCGTGA
M. caprae specific Probe M. caprae probe Cyan 500- TATCGGGTACACAAAGACGA
-BBQ
lpqT_FW Forward sequencing primer,
forward real-time PCR assay primer
ACGAATCCGGCGATGATC
lpqT_RV Reverse sequencing primer, reverse real-time PCR assay primer CGACTGCACACCTGGAA
lpqT Probe M. caprae, M. bovis, M. bovis BCG probe FAM-TTGGCCGGCGCCGGTT-BHQ1
RD1_Fw Forward sequencing primer,
forward real-time PCR assay primer
CATCGCTGATGTGCTTGC
RD1_Rv Reverse sequencing primer, reverse real-time PCR assay primer TGCGCCGAGCTGTATTC
RD1 Probe Absence of M. bovis BCG HEX-ACACTAGCGTCAATGCGGTCA-BHQ1
IAC_Fw Forward sequencing primer,
forward real-time PCR assay primer
TCACCGACCATGTCCAG
IAC_RV Reverse sequencing primer, reverse real-time PCR assay primer CGTTGCCCAATCCGTATG
IAC probe IAC probe CY5-CAGCAGTACCATCGCCATCG-BHQ2
doi:10.1371/journal.pone.0023481.t001
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strains, provided by Professor Mario Vaneechoutte (University of
Ghent, Ghent, Belgium), were clinical isolates collected over a ten
year period from reference laboratories in Belgium and the
Netherlands. These isolates were characterised on the basis of
custom techniques available at the time. Twenty eight NTM were
purchased from the German Collection of Microorganisms and
Cell Cultures (Deutsche Sammlung von Mikroorganismen und
Zellkulturen GmbH, DSMZ) and grown on Middlebook agar/
broth at the appropriate temperature (either 30uC or 37uC). Fast
growing mycobacteria were cultured for 3-6 days and slow
growing mycobacteria were incubated for six weeks, or until
sufficient growth was visible. All media were purchased from BD
Biosciences (Oxford, United Kingdom). DNA was supplied from
the 16 remaining NTM and 4 of the 5 Norcardia strains by
Professor Vaneechoutte and these species were characterised using
techniques previously described [31,32,33].
DNA isolation and quantification
Genomic DNA from 28 NTM and 2 M. bovis BCG cultures was
isolated from 1 ml of culture (Middlebrook 7H9 broth, Becton
Dickinson), using a technique previously described in the literature
[23]. Total genomic DNA samples provided by the RIVM were
extracted according to Van Soolingen et al. [34], whereas total
genomic DNA samples from the National Reference Centre for
Mycobacteria, Borstel were extracted as described by van Embden
et al. [35], while genomic DNA provided by Professor Vanee-
choutte was extracted as described by De Baere et al. [31]. For all
other bacterial species tested, DNA was provided from stocks held
within this laboratory (Microbiology, NUIG). DNA concentrations
for all species and strains used in this study were determined using
the PicoGreen dsDNA Quantitation Kit (Molecular Probes, Eugene,
Oregon, USA) and the TBS-380 mini-fluorometer (Invitrogen
Corporation, California, USA). DNA samples were stored at
220uC before use.
Conventional and real-time PCR primers and hydrolysis
probe design
Oligonucleotide primers and hydrolysis probes were designed in
accordance with general recommendations and guidelines [36,37],
following alignments of each of the nucleic acid diagnostics target
genes identified in this study. Primers and probes (Table 1) were
supplied by MWG-BIOTECH AG (Essenberg, Germany) or TIB
MOLBIOL (Berlin, Germany). Primers were designed to have a
melting temperature (Tm) of 58–61uC and the probes were designed
to have a Tm 4–7uC higher. The probe designed to identify M. bovis,
M. bovis BCG and M. caprae had a higher Tm (69.8uC) due to a
particularly G/C rich target region. Hydrolysis probes were
designed to be specific for each target following published design
guidelines [36]. Assay oligonucleotides were designed with similar
properties such that monoplex assays could be easily multiplexed
after specificity and sensitivity testing was complete [23].
The M. caprae specific assay PCR primers, MTC_Fw (position
618–634 bp of the lepA gene of M. tuberculosis H37Rv) and
MTC_Rv (position 754–772 bp), were designed to amplify a
155 bp fragment of the lepA gene. lpqT_FW and lpqT_RV were
designed to amplify a 141 bp fragment of the lpqT gene for the
identification of M. bovis, M. bovis BCG and M. caprae (positions 17–
34 bp and 146–162 bp of the M. tuberculosis H37RV lpqT gene).
The RD1 assay was designed to amplify a 117 bp region of the
Rv3876 gene, a conserved hypothetical protein, part of RD1,
absent in all M. bovis BCG strains. The RD1_Fw primer was
located at position 1416–1433 bp and the reverse primer RD1_Rv
between 1516–1532 bp of the M. tuberculosis H37 Rv 3876 gene.
The internal amplification control (IAC) PCR primers, IAC_Fw
and IAC_Rv, were designed to amplify a 157 bp region of the M.
smegmatis MSMEG_0660 gene. The IAC_Fw primer was located
at positions 497–513 bp and the reverse primer between positions
636–653 bp.
All real-time PCR assays were initially tested for in a monoplex
format, evaluating their specificity and sensitivity using probes
labelled with FAM and Black Hole Quencher 1 (BHQ1). After
optimisation of the monoplex real-time PCR assays, three of the
four assay probes were labelled with different fluorescent dyes to
allow for incorporation into a multiplex real-time PCR format.
The M. caprae specific probe was labelled with cyan500 and BBQ,
the M. bovis/M. bovis BCG/M. caprae specific probe with FAM and
BHQ1, the M. bovis/M. caprae probe with HEX and BHQ2 and
the IAC probe with Cy5 and BHQ2.
Conventional PCR
Conventional PCR was performed using the sequencing
primers outlined in Table 1 on the iCycler iQ thermal cycler
(Bio-Rad Laboratories Inc., California, USA). All reactions were
carried out in a final volume of 50 ml, containing 5 ml 106buffer
(15 mM MgCl2), 1 ml forward and reverse primers (0.2 mM final
conc.), 2 ml Taq DNA polymerase (1 U/ml, Roche Diagnostics,
Basel, Switzerland), 1 ml dNTP mix [(10 mM deoxynucleoside
triphosphate set (Roche Diagnostics)], 2 ml of template DNA and
38 ml nuclease free water (Applied Biosystems/Ambion, Texas,
USA). The cycling parameters consisted of initial denaturation at
95uC for 5 mins, followed by 35 cycles of denaturation at 95uC
(1 min), annealing at 50uC (1 min), and extension at 72uC (1 min),
with a final elongation step at 72uC for 10 min.
Sequencing
Nucleotide sequence data for real-time PCR assay design was
generated in this study or was obtained from the National Centre
for Biotechnology Information (NCBI- http://www.ncbi.nlm.nih.
gov/), or the Sanger website (where partial nucleotide sequences
for M. canettii, M. africanum and M. microti were available). Real-time
PCR assay primers were used to generate nucleotide sequence
information for each of the assays developed. Sequencing primers
were also designed to span the full gene sequence of lpqT, lepA and a
number of other genes to identify potential candidate nucleic acid
diagnostics targets for the specific identification of M. caprae.
PCR products were generated according to section 2.5, purified
using the High Pure PCR Product Purification Kit (Roche
Diagnostics) and sequenced commercially (Sequiserve, Vaterstet-
ten, Germany).
Development of an IAC for real-time PCR
A non-competitive IAC [38] was designed and incorporated
into the multiplex real-time PCR. The M. smegmatis MSMEG_0660
gene was chosen as the target as it is specific to M. smegmatis,
avoiding any possible cross reaction. Titration of IAC DNA was
performed to determine the optimum concentration per reaction
that could be reliably detected in the presence of MTC DNA, yet
not inhibit detection of low concentrations of the primary assay
targets. An IAC concentration of 100 genome equivalents per
reaction was determined as optimum.
Real-time PCR
Monoplex real-time PCR was performed on the LightCycler 2.0
Instrument (Roche Diagnostics) using the LightCyclerH TaqManH
Master kit (Roche Diagnostics). Each reaction contained 56
master mix, forward and reverse primers (0.5 mM final conc.),
FAM labelled probe (0.2 mM final conc.), template DNA (2 ml) and
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nuclease free dH2O to a final volume of 20 ml. The cycling
parameters consisted of 10 min incubation at 95uC to activate the
Taq, 50 cycles of 95uC for 10 s and 60uC for 30 s, followed by a
cooling step at 40uC for 10 s. The temperature transition rate for
all cycling steps was 20uC/s.
Multiplex real-time PCR reactions were carried out on the
LightCycler 480 using LightCyclerH 480 Probes Master kit (Roche
Diagnostics). The optimised PCR mix contained 26 LightCycler
480 Probes Master (6.4 mM MgCl2), forward and reverse primer
(0.5 mM final conc.), Cyan500, FAM, HEX and CY5 labelled
probes (0.2 mM final conc.), dimethyl sulfoxide (4%, Sigma-
Aldrich Missouri, USA), template DNA (MTC: 2 ml; IAC: 2 ml;
NTM: 10 ml) adjusted to a final volume of 40 ml with the addition
of nuclease free dH2O. The M. smegmatis internal control DNA was
diluted to contain 100 genome equivalents per 2 ml and NTM
DNA was diluted to contain ,104 genome equivalents per 10 ml.
The cycling parameters used were the same as those used on the
LightCycler 2.0. The temperature transition rate, referred to as
the ramp rate on the LightCycler 480 was 4.4uC/s while heating
and 2.2uC/s while cooling. Prior to experimental analysis on the
LightCycler 480, a colour compensation file was generated, to
avoid fluorescence leaking from channel to channel, using the
technical note outlined in the Advanced Software Functionalities
of the operator manual [39].
Results
Diagnostics target identification
The diagnostics target used for the specific identification of M.
caprae was the lepA (Rv 2404c) gene. In-silico analysis of nucleotide
sequences generated in this study revealed a single nucleotide
polymorphorism (SNP) at position 690 bp of the M. tuberculosis
H37Rv lepA gene which was specific for M. caprae. LepA is an
essential bacterial elongation factor. The lepA gene codes for a
highly conserved protein present in all bacteria sequenced to date,
with a homologue (Guf1) found in higher organisms [40]. The M.
caprae specific SNP, identified from nucleotide sequence data
generated in this study, was a C to T substitution which was
conserved in all 5 strains of M. caprae tested.
The diagnostics target identified in this study for collective
identification of M. bovis, M. bovis BCG and M. caprae was the lpqT
(Rv1016c) gene. LpqT belongs to a group of lipoproteins which
are present in all bacteria [41] and is thought to be required for
optimal growth of mycobacteria in vivo [42]. In-silico analysis of
publicly available lpqT nucleotide sequences, performed in this
study, revealed a 5 bp region of lpqT, deleted in M. bovis and M.
bovis BCG but present in M. tuberculosis, M. canettii, M. africanum and
M. microti. Sequence information was generated for the lpqT gene
in M. caprae and M. pinnipedii which confirmed the deletion was also
present in M. caprae but not M. pinnipedii.
The diagnostics target used to differentiate M. bovis BCG from
M. bovis and M. caprae was the Rv3876 gene, which is part of
Region of Difference 1 (RD1). Regions of Difference (RD) in the
Mycobacterium tuberculosis complex refer to regions of the genome
present in M. tuberculosis but deleted from M. bovis BCG [43]. The
particular RD targeted in this study (RD1), has been shown to be
deleted in all M. bovis BCG strains and has been linked to the
attenuation of this strain [13]. Any region of RD1 could
potentially be incorporated into this multiplex real-time PCR
and used with the novel diagnostics targets described above.
Assay design and development
While the guidelines for primer and probe design were adhered
to as closely as possible, the high G/C content (60–65%) of the
Mycobacterium species had an impact on assay design. The lpqT
specific probe was designed spanning the deletion junction of a
region deleted in M. bovis, M. bovis BCG and M. caprae and present
in the other members of the MTC, that was very G/C rich,
making probe design difficult. The lpqT probe, therefore, had a
relatively high Tm, however this did not impact on assay
performance. The M. caprae specific probe targeted an SNP in
the lepA gene. Avoiding cross reaction of the M. caprae probe with
other members of the MTC proved challenging. A number of
probes were designed and tested and the optimum probe was
chosen empirically based on specificity and sensitivity results. The
optimum probe was designed complementary to the + strand of
the lepA gene as the resulting G/A mismatch, that occurred in the
presence of non-target MTC DNA, was more destabilising to the
probe than the C/T mismatch, hence improving specificity. The
probe was designed to have a Tm of 60.1uC, only slightly above
the annealing temperature of the assay (60uC), allowing the probe
to hybridise to exactly matched sequence only, therefore
maximising the specificity effect of the SNP. This did, however,
slightly reduce probe binding efficiency, leading to a small
reduction in sensitivity.
Internal amplification control
In order for a result to be considered valid using this assay, a
positive signal must be obtained in the Cy5 detection channel on
the LightCycler 480. If the IAC is not detected, the result is
considered invalid and must be repeated [38,44]. For the purposes
of this study, M. smegmatis DNA was spiked into the PCR master
mix to act as an internal control target. Alternatively, M. smegmatis
cultured cells could be used as a process control, spiked into
patient samples before genomic DNA isolation. In this design, the
M. smegmatis cells would serve as both an extraction control and an
amplification control and could be used when testing patient
samples.
Specificity of the diagnostic assays
The specificity of each real-time PCR assay was confirmed both
in monoplex and multiplex formats using the specificity panel
listed in supplementary Table S1 and Table S2. The lepA assay was
specific for the detection of the 5 M. caprae strains in our collection
(Figure 1 A). The remaining members of the MTC, NTM and
other bacteria tested were not detected. The M. bovis, M. bovis BCG
and M. caprae assay was also specific, detecting only target species
(Figure 1 B). The diagnostics assay targeting RD1 did not detect
any of the 7 M. bovis BCG strains tested for (Figure 1 C) but
detected all M. bovis and M. caprae strains tested for, allowing for
the specific identification of M. bovis BCG. All remaining members
of the MTC (with the exception of the 5 M. microti and one M.
canettii) were detected. None of the NTM or other bacteria on the
specificity panel were detected using the RD1 assay.
The IAC assay targeted the M. smegmatis MSMEG_0660 gene.
This assay was tested against all members of the MTC and NTM
and was specific for the detection of M. smegmatis. One hundred
genome equivalents of M. smegmatis DNA was added to all samples
tested, to control for PCR inhibition, and was detected in all
samples (Figure 1 D). Table 2 describes how to interpret the results
of the multiplex real-time PCR assay.
Sensitivity of the assays
The limit of detection (LOD) of each assay was evaluated in a
monoplex real-time PCR format. Genomic DNA was quantified
and serial dilutions were prepared from 200,000 to 2 genome
equivalents (with an estimated genome size of 4.5 million base
pairs, one M. caprae cell contains approximately 5.0 fg DNA [45]).
Bovine Tuberculosis in Humans
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Assay sensitivity testing was performed using M. caprae DNA as it is
detected in all of the multiplex assays.
In a monoplex format, the dilution series was run in duplicate
and a sensitivity of 2- 20 M. caprae genome equivalents was
determined for each assay. In multiplex format the lower limit of
detection was established using probit regression analysis. Twelve
replicates of each of 20, 15, 12, 10, 7.5, 4, 2 and 0.2 M. caprae
genome equivalents were tested. LOD’s of 3.95 and 3.55 genome
equivalents were determined (95% probability) for the M. bovis/M.
bovis BCG/M. caprae and the M. bovis/M. caprae assays respectively.
However, these dilutions were not appropriate to determine the
M. caprae specific assay LOD. The analysis was repeated using
concentrations of 200, 100, 75, 50, 25, 15, 10 and 5 genome
equivalents of M. caprae DNA. An LOD of 14.77 genome
Figure 1. Amplification curves for multiplex real-time PCR assay. Figure 1 A. Real-time amplification curves for M. caprae (circle) using lepA
gene in Cyan500 channel (450–500). Figure 1 B Amplification curves for M. caprae (circle), M. bovis (triangles) and M. bovis BCG (diamonds) using the
lpqT gene in FAM channel (483–533). Figure 1 C Amplification curves for all members of the MTC with the exception of M. bovis BCG (diamonds) and
M. microti in the HEX channel (523–568). Figure 1 D Amplification curves for IAC in Cy5 channel (615–670) with the no template control highlighted
with stars through amplification curve.
doi:10.1371/journal.pone.0023481.g001
Table 2. Result interpretation table.
Analysis channel result Diagnostics test result
Cyan 500
(+ve indicates
presence of
M. caprae)
FAM
(+ve indicates presence
of M. bovis, M. bovis BCG
or M. caprae)
HEX
(-ve indicates presence
of M. bovis BCG if positive
in FAM channel)
Cy5
(IAC)
+ ve + ve + ve + ve M. caprae present
- ve + ve + ve + ve M. bovis present
- ve + ve - ve + ve M. bovis BCG present
- ve - ve + ve + ve MTC member other than M. caprae,
M. bovis, M. bovis BCG or M. microti
- ve - ve - ve - ve Result invalid and test must be repeated
doi:10.1371/journal.pone.0023481.t002
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equivalents (95% probability) was determined for the M. caprae
specific assay when tested as part of the multiplex. The IAC, at a
concentration of 100 genome equivalents per reaction, was
included in all samples during sensitivity testing and was detected
as expected.
Discussion
The WHO [46] defines zoonoses as infections and diseases
which can be transmitted naturally from animals to humans. A
recent WHO report highlights the difficulties in the diagnosis of
such diseases and suggests that the true incidence of many
neglected zoonoses, including zoonotic TB, may be greatly
underestimated [46]. Zoonotic TB in humans is most commonly
caused by M. bovis and to a lesser extent M. caprae (prevalent in
certain regions in Europe [47]). Human TB infection caused by
the zoonotic transmission of M. microti and M. pinnipedii has also
been reported [48,49,50]. While bovine TB in humans is
considered rare in developed countries, it has been described as
an ‘endemic neglected zoonoses’ in developing countries [51]. In
these settings, the true incidence of zoonotic TB in humans
remains largely unknown due to inabilities in hospital laboratories
to distinguish between the causative agent of infection, a scarcity of
trained personnel, financial constraints in addition to limited
control measures in place [51,52].
M. bovis is the predominant member of the MTC associated
with bovine TB infection. However, it also has been isolated from
and is the causative agent of TB in a wide range of mammalian
hosts including humans, goats, dogs, deer and ferrets [10]. Trans-
mission to and infection of human hosts with M. bovis can result
from zoonotic exposure to TB infected animals or to consumption
of unpasteurised dairy products [8]. Recent studies have also
shown that human to human transmission of M. bovis can also
occur, but is considered rare [53].
Since its transfer from M. tuberculosis subsp caprae to M. bovis
subsp caprae in 2002 [5], this member of the MTC has been
recognised as the cause of a number of outbreaks of TB in animals
such as goats, cattle and red deer [47]. In addition, M. caprae has
been associated with outbreaks of TB in humans in a number of
European countries [54,55,56] and was shown to be the true
causative agent of one third of human M. bovis associated TB cases
in Germany between 1999–2001 [10].
M. bovis BCG, the commonly used vaccine strain, has also been
implicated in human disease particularly in immunocompromised
patients, such as HIV positive and cancer patients, where it has
been shown to cause disseminated disease [57], and in children
who have been vaccinated in endemic TB areas [58].
While the members of the MTC discussed above share many
phenotypic characteristics, in addition to natural host preference,
M. bovis, M. bovis BCG and M. caprae exhibit a differential intrinsic
susceptibility profile to pyrazinamide (PZA), an important first line
anti-TB drug responsible for reducing patient treatment time [59].
M. bovis and M. bovis BCG are intrinsically resistant to PZA
whereas M. caprae is sensitive to PZA [5]. This highlights the need
for a rapid test that can detect the MTC and differentiate between
its members so that the clinician can choose the appropriate
chemotherapy for the patient. More accurate diagnosis and
treatment will protect against the development of drug resistant
TB and reduce morbidity and mortality [10]. Furthermore,
accurate identification of these organisms allows monitoring of
these neglected members of the MTC with respect to prevalence,
transmission and global distribution [48]. Also, differentiation of
the complex could contribute to the better understanding of the
clinical relevance of these members of the MTC.
Currently, there is only one commercially available diagnostics
kit for the differentiation of the MTC, the GenoType MTBC line
probe assay (Hain Lifesciences). This assay differentiates mem-
bers of the MTC utilising highly conserved SNP’s in the gyrB gene
[60], however it is limited as it does not differentiate M. canettii
and M. pinnipedii. Literature describing NAAT’s for the complete
differentiation of the MTC [50,61,62,63] are hindered by the
complexity of the multiple reactions required, the inability to
differentiate between some members of the MTC, in addition
to the complex interpretation of the results generated. While
SNP’s have commonly been used for accurate differentiation of
members of the MTC [3,50] further validation of the SNP
identified in this study for the specific detection of M. caprae is
required.
The multiplex real-time PCR assay described in this study is the
first description of a real-time PCR diagnostics assay for the
identification and simultaneous differentiation of M. bovis, M. bovis
BCG and M. caprae using novel diagnostics targets in one internally
controlled reaction. This diagnostics assay takes approximately
one hour to perform after DNA extraction. The assay has been
validated against a large panel of well characterised clinical
isolates. In its current format, this multiplex real-time PCR assay
would be applied to MTC clinical isolates for the identification of
the most common causes of zoonotic TB. Monitoring bovine TB
in humans is valuable for guiding public health policy and is
important for the study of zoonotic TB epidemiology.
The developed assay also has the potential to be used directly in
sputum samples following identification of an efficient sputum
sample preparation method. If performing direct sputum testing,
the assay developed in this study would be used as a follow on test
in combination with a real-time PCR assay for identification of the
MTC and differentiation of M. tuberculosis and M. canettii, which
was previously developed by this group. More specifically, if a
patient sample is identified as positive for the presence of the MTC
but M. tuberculosis or M. canettii negative, the assay developed in this
study can then be used to determine if sample contains M. bovis, M.
bovis BCG or M. caprae, the most common causes of zoonotic TB in
humans.
The study presented here focuses on accurately differentiating
members of the MTC most commonly associated with zoonotic
human TB infection. However, there is a need to differentiate be-
tween all members of the MTC to supply unambiguous epide-
miological data as to the true prevalence of each member of the
MTC causing TB infection [3]. Work has begun in this group on
the development of a final multiplex real-time PCR diagnostics
assay for the accurate identification of M. africanum, M. microti and
M. pinnipedii. This will complete a cassette of three multiplex real-
time PCR diagnostics assays for the identification and differenti-
ation of all members of the MTC.
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